Optimization of AAV process development: transfection matters

With the increased number of therapeutic rAAV candidates reaching clinical trial pipeline, there is demand for innovative technologies to improve process development and facilitate manufacturing scale-up future commercialization. To this end, Polyplus-transfection has worked hand-in-hand with viral vector manufacturers develop a transfection reagent specifically large scale in suspension cell systems: FectoVIR®-AAV. FectoVIR®-AAV aims processes by boosting productivity, bringing flexibility facilitating scalability. Here, we share preliminary data from Allergan Biologics’ recent evaluation against their current AAV production platform. Analysis physical titers revealed 3-fold increase both particles (VP) genome (VG) per ml culture when using compared PEIpro®.